Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Molina Dayal

Reproductive Endocrinology St. Louis, MO Medical Doctor

NPI 1124092556 CMS profile 96656

555 New Ballas Rd, Ste 150, St. Louis, MO 63141

Open in the dashboard

General payments

$13,574

98 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Molina Dayal of St. Louis, MO is reported in the CMS Open Payments database as having received $13,574 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $326 12
2024 General $214 8
2023 General $308 11
2022 General $10,775 20
2021 General $179 9
2020 General $1,374 5
2019 General $398 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Molina Dayal
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Molina Dayal were reported at $326. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Molina Dayal Reproductive Endocrinology median Middle half National median
2019 $398 $196 $77–$425 $163
2020 $1,374 $81 $35–$182 $114
2021 $179 $102 $43–$247 $132
2022 $10,775 $139 $62–$303 $149
2023 $308 $141 $65–$285 $160
2024 $214 $144 $65–$302 $164
2025 $326 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $12,195 26 payments
  2. Organon LLC $568 20 payments
  3. EMD Serono, Inc. $351 30 payments
  4. Merck Sharp & Dohme Corporation $188 10 payments
  5. Galen US Inc $73 4 payments
  6. Hamilton Thorne, Inc. $56 2 payments
  7. Astellas Pharma US Inc $50 1 payment
  8. CooperSurgical, Inc. $25 1 payment
  9. Hologic, LLC $23 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $20 1 payment
  11. Other $25 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,258 2 payments
  2. Food and Beverage $2,019 91 payments
  3. Travel and Lodging $1,297 5 payments
Products named General payments · program years 2019–2025
  1. MENOPUR Reproductive Health $10,759 19 payments
  2. INVOCELL $1,311 1 payment
  3. FOLLISTIM AQ Follitropin $463 15 payments
  4. GANIRELIX ACETATE $316 10 payments
  5. Gonal-f $192 21 payments
  6. FOLLISTIM AQ Womens Health $188 10 payments
  7. MENOPUR Reproductive Health $125 6 payments
  8. GANIRELIX $104 6 payments
  9. SYNERA $73 4 payments
  10. LENSHOOKE SEMEN QUALITY ANALYZER $56 2 payments
  11. Other $529 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record